Endocrine therapy, developed to block hormone-driven tumor growth, is effective in reducing the risk of disease recurrence and death of hormone-receptor positive tumors, but not in hormone-receptor negative tumors [22]. This evidence concerns the gene NR4A1 and neoplasm.